Loading company…
Re-Aim Therapeutics develops targeted biologics for T cell-driven autoimmune diseases.
Founded in 2024 and based in Oxford, Re-Aim Therapeutics develops therapies that target disease-associated T cells. Its lead monoclonal antibody candidate, REA-001, is designed to selectively deplete pathogenic T cells. In May 2026, it raised GBP 7 million in Seed funding co-led by Syncona and Oxford Sciences Enterprises to advance REA-001 and expand its pipeline.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in